Jollifos 50mg Capsule uses for treating leishmaniasis, a parasitic disease spread by sandflies, including the most severe form known as kala-azar (visceral leishmaniasis), which impacts internal organs. It is suitable for adults and adolescents aged 12 and older who weigh at least 30 kg (66 lbs) and is specifically indicated for visceral leishmaniasis caused by Leishmania donovani and cutaneous leishmaniasis due to Leishmania braziliensis.

Jollifos 50mg Capsule is also effective against various forms of leishmaniasis, including cutaneous, visceral, and mucosal types. It also targets infections from free-living amoebas such as Naegleria fowleri and Balamuthia mandrillaris.

Jollifos 50mg Capsule effectively targets Leishmania parasites through several key mechanisms. It disrupts the parasite's cell membranes by interacting with lipids, compromising their structural integrity. By inhibiting cytochrome c oxidase in the mitochondria, Jollifos 50mg Capsule hampers the parasite's energy production. It also induces a form of cell death similar to apoptosis, further aiding in the elimination of the parasites. Together, these actions significantly reduce the viability of Leishmania, making Jollifos 50mg Capsule is a powerful treatment option for leishmaniasis.

1. Aluminum or Magnesium Antacids (Moderate)
   These antacids may reduce Jollifos absorption and lower its effectiveness. Take them at least 2 hours apart or as advised by your doctor.

2. Tetracycline Antibiotics (Severe)
   Concurrent use may decrease absorption of both drugs, reducing their effectiveness. Avoid taking together unless instructed by your healthcare provider.

3. Warfarin (Moderate)
   Jollifos may enhance the anticoagulant effect of Warfarin, increasing the risk of bleeding. Regular INR monitoring is recommended.

4. Levodopa (Moderate)
   This combination may reduce the effectiveness of Levodopa in treating Parkinson’s symptoms. Dose adjustment may be required.

5. Ceftriaxone (Moderate)
   Concurrent use may interfere with mineral absorption or effectiveness. Use only under medical supervision.

• Store JJollifos 50mg capsule at room temperature between 20°C to 25°C.

• Keep it out of sight and reach of children and pets.

• Store it in the original container.

• Protect it from moisture, heat, and direct sunlight.

Take Jollifos 50mg capsule orally with food to help reduce gastrointestinal side effects. If you weigh between 30 and 44 kg, take one 50 mg capsule twice daily for 28 consecutive days. If you weigh 45 kg or more, take one 50 mg capsule three times daily for the same duration. Follow this dosing schedule closely to ensure effective treatment for leishmaniasis. Regularly check in with your doctor to monitor your response and address any potential side effects.

Like all medications, Jollifos 50mg capsule can cause side effects, although not everyone who takes it will experience them.

Common side effects of Jollifos 50mg capsule may include:

• Nausea & Vomiting

• Diarrhea

• Abdominal pain

• Decreased appetite

• Dizziness

• Headache

• Sleepiness

• Skin itching

• Abnormalities in liver or kidney tests

Serious side effects of Jollifos 50mg capsule include:

• Fertility problems

• Testicular pain and absent or decreased ejaculation

• Kidney and liver problems

• Serious skin problems (e.g., Stevens-Johnson Syndrome)

• Decrease in platelets

• Inform your doctor if you have a history of kidney or liver issues, as close monitoring may be required during treatment.

• Regularly check for gastrointestinal symptoms and maintain proper hydration to prevent dehydration.

• Report any skin reactions or signs of low blood cell counts to your healthcare provider immediately.

• Always disclose all medications you are taking to avoid potential drug interactions.

• Use Jollifos 50mg capsule during pregnancy only when necessary, and report any allergic reactions or concerns promptly.

1. Efficacy and Tolerability of Miltefosine in the Treatment of Cutaneous Leishmaniasis - PMC (nih.gov)
2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204684s000lbl.pdf
3. https://ncvbdc.mohfw.gov.in/WriteReadData/l892s/Guidelines_on_miltefosine.pdf
4. https://pubmed.ncbi.nlm.nih.gov/10588964/https://pubmed.ncbi.nlm.nih.gov/10588964/